Impact of glucagon-like peptide 1 receptor agonist liraglutide and dipeptidyl peptidase-4 inhibitor sitagliptin on bowel cleaning and gastrointestinal symptoms in type 2 diabetes

被引:9
|
作者
Tong, Yan [1 ]
Huang, Jian Qing [1 ]
Chen, Yang [1 ]
Tu, Mei [1 ]
Wang, Wei [1 ]
机构
[1] Fujian Med Univ, Longyan Affiliated Hosp 1, Longyan, Fujian, Peoples R China
关键词
liraglutide; sitagliptin; bowel preparation quality; gastrointestinal discomfort; gastrointestinal motility; DOSE POLYETHYLENE-GLYCOL; GLUCOSE; COLONOSCOPY; EXENATIDE; SUPERIOR; MOTILITY; TRANSIT;
D O I
10.3389/fphar.2023.1176206
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 inhibitors (DPP-4i) profoundly affect the gastrointestinal motor system, which may increase the incidence of inadequate bowel cleaning and gastrointestinal symptoms. Hence, this observational study mainly aimed to assess the influence of GLP-1 RAs liraglutide and DPP-4i sitagliptin on bowel preparation in type 2 diabetes (T2DM). Method: This observational study consecutively enrolled T2DM scheduled for a colonoscopy. Participants were prospectively separated into the liraglutide group (n = 120), sitagliptin group (n = 120), and control group (n = 120) based on the current hypoglycemic regimen. 3L split-dose polyethylene glycol regimens were used for bowel preparation. Experienced gastrointestinal endoscopists conducted colonoscopies. Lawrance Bowel-Preparation Tolerability Questionnaire and Boston Bowel Preparation Scale (BBPS) were conducted to assess bowel cleaning quality, tolerability, and safety. Results: The incidence of inadequate bowel cleaning was 17.5% in the liraglutide group, 20.5% in the sitagliptin group, and 21.7% in the control group. The difference among the three groups was not statistically significant (p = 0.927). Meanwhile, there were no significant differences in the mean BBPS, cecal intubation time, and polyp-detecting rates among the three groups (all p > 0.0.05). Nausea, vomiting, and bloating scores were increased in the liraglutide group compared with the other two groups (p < 0.05), whereas most were mild or very mild. Subgroup analyses showed that the incidence of inadequate bowel cleaning in T2DM with diabetic peripheral neuropathy (DPN) was increased in the liraglutide group compared with the sitagliptin group (61.3% vs. 32.1%, p = 0.022) and control group (61.3% vs. 32.8%, p = 0.025). Conclusion: GLP-1RA liraglutide or DPP-4i sitagliptin did not significantly increase the incidence of inadequate bowel cleaning and gastrointestinal symptoms during bowel preparation. Liraglutide may increase the incidence of inadequate bowel preparation in patients with DPN. This study reveal that more attention and aggressive bowel preparation regimens should be given to the T2DM with DPN.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] The efficacy and safety of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 agonists in pediatric patients with type 2 diabetes: a systematic review
    Li, Xinyi
    Sun, Tong
    Du, Xin
    Xie, Xiaohui
    Shi, Luwen
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2022, 35 (12): : 1457 - 1463
  • [32] Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus
    Thondam, S. K.
    Cross, A.
    Cuthbertson, D. J.
    Wilding, J. P.
    Daousi, C.
    DIABETIC MEDICINE, 2012, 29 (08) : E205 - E210
  • [33] Effectiveness of switching from dipeptidyl peptidase-4 inhibitor to oral glucagon-like peptide-1 receptor agonist in Japanese participants with type 2 diabetes mellitus: Prospective observational study using propensity score matching
    Iwamoto, Hideyuki
    Kimura, Tomohiko
    Fushimi, Yoshiro
    Iwamoto, Masahiro
    Tatsumi, Fuminori
    Sanada, Junpei
    Iwamoto, Yuichiro
    Katakura, Yukino
    Shimoda, Masashi
    Nakanishi, Shuhei
    Mune, Tomoatsu
    Kaku, Kohei
    Kaneto, Hideaki
    DIABETES OBESITY & METABOLISM, 2024, 26 (10): : 4366 - 4374
  • [34] RESHAPING DIABETES CARE: THE FUNDAMENTAL ROLE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN CLINICAL PRACTICE
    Umpierrez, Guillermo E.
    Meneghini, Luigi
    ENDOCRINE PRACTICE, 2013, 19 (04) : 718 - 728
  • [35] Cardiovascular Preventing Effects of Dipeptidyl Peptidase-4 Inhibitors: Beyond Glucagon-Like Peptide-1
    Wang, Xi-Mei
    Yang, Yue-Jin
    Wu, Yong-Jian
    AMERICAN JOURNAL OF CARDIOLOGY, 2012, 110 (10): : 1551 - 1551
  • [36] The utilization pattern of glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor, and sodium glucose cotransporter-2 inhibitors in type 2 diabetes mellitus in a tertiary care hospital-A retrospective study
    Prathiksha, A. S.
    Dakshin, Priyanka
    Acharya, Leelavathi D.
    Thunga, Girish P.
    Poojari, Pooja G. Gopal
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 349 - 349
  • [37] Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: Focus on sitagliptin
    Herman, G. A.
    Stein, P. P.
    Thornberry, N. A.
    Wagner, J. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (05) : 761 - 767
  • [38] Dipeptidyl Peptidase 4 Inhibitor Sitagliptin Protects Endothelial Function in Hypertension Through a Glucagon-Like Peptide 1-Dependent Mechanism
    Liu, Limei
    Liu, Jian
    Wong, Wing Tak
    Tian, Xiao Yu
    Lau, Chi Wai
    Wang, Yi-Xiang
    Xu, Gang
    Pu, Yunfei
    Zhu, Zhiming
    Xu, Aimin
    Lam, Karen S. L.
    Chen, Zhen Yu
    Ng, Chi Fai
    Yao, Xiaoqiang
    Huang, Yu
    HYPERTENSION, 2012, 60 (03) : 833 - 841
  • [39] Dipeptidyl Peptidase-4 Inhibitor, Des-Fluoro-Sitagliptin, Improved Endothelial Function through Enhancing Action of Glucagon-Like Peptide-1 in vivo and in vitro
    Matsubara, Junichi
    Sugiyama, Seigo
    Nakamura, Taishi
    Kurokawa, Hirofumi
    Ohba, Keisuke
    Maeda, Hirofumi
    Kim-Mitsuyama, Shokei
    Ogawa, Hisao
    CIRCULATION, 2011, 124 (21)
  • [40] Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes
    Hanefeld, Markolf
    Herman, Gary A.
    Wu, Mei
    Mickel, Carolyn
    Sanchez, Matilde
    Stein, Peter P.
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (06) : 1329 - 1339